Teva Launches Metoclopramide Injection

Teva Launches Metoclopramide Injection
Teva Launches Metoclopramide Injection

Teva announced the launch of Metoclopramide Injection, the generic version of Baxter's Reglan injection.

Metoclopramide is an antidopaminergic indicated for relief of symptoms associated with acute and recurrent diabetic gastric stasis, prophylaxis of vomiting associated with emetogenic cancer chemotherapy, prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable, to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers, and to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine.

RELATED: FDA Approves First Generic Nexium

Metoclopramide works by stimulating motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. It also increases the tone and amplitude of gastric contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. In addition, it increases the resting tone of the lower esophageal sphincter.

Metoclopramide Injection is available as a 5mg/mL strength in 2mL single-use vials.

For more information call (888) 838-2872 or visit TevaGenerics.com.

Loading links....